Pulling SEC filings + quote and writing the call…
VRDN
Viridian Therapeutics, Inc.DE
Next earnings Aug 4, 2026 · consensus $-1.07 EPS, $13.9K rev
Last earnings +33.4% on 2026-05-05
$17.52
▲ +5.35%$16.63▲ +4.33%
over 1Y
L $13.30EODHDH $33.78
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+5.4%
1W+3.0%
1M+4.1%
3M-40.3%
YTD-45.8%
1Y+4.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 23 analysts
Buy
Revenue grew 23359.9% YoY; but unprofitable (net margin -483.6%).
Viridian Therapeutics, Inc.DE shows $70.8M in FY2025 revenue (+23359.9% YoY), a -483.6% net margin, and -47.4% ROE.
Sources: SEC EDGAR (CIK 0001590750, latest 10-Q filed 2026-05-05) · EODHD · as of 6/22/2026, 5:45:43 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.